Spain R, Powers K, Murchison C, et al. Neurol Neuroimmunol Neuroinflamm. 2017 Jun 28;4(5):e374.

The annualized percent change in brain volume was significantly less in secondary progressive MS patients administered alpha lipoic acid, compared to placebo.